NOF CORPORATION and Phosphorex Collaborate to Supply Lipid Nanoparticle Formulations
Using NOF’s Proprietary Ionizable Lipid, COATSOME® SS Series

Tokyo, Japan, Hopkinton, MA - April 30, 2024 – NOF CORPORATION announced today a collaboration
with Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contractdevelopment and manufacturing organization (“CDMO”), to supply lipid Nanoparticle (LNP)
formulations using NOF’s proprietary ionizable lipids, COATSOME® SS Series, further enhancing its
leading position in providing LNP based drug delivery solutions to the market.
NOF CORPORATION’s COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA,siRNA, and pDNA. These proprietary ionizable lipids offer efficient drug delivery into the cytoplasm ofcells with higher biodegradability and low toxicity, with controlled targeting to organs such as theliver, spleen, and lymph nodes.
Phosphorex has extensive experience as a CDMO for LNPs, and the combination of NOF’s lipid
technology and Phosphorex's LNP manufacturing technology will enable us to provide comprehensive
services related to LNP material development, formulation development, and scale-up manufacturing.
About NOF CORPORATIONThe NOF Group pursues multi-faceted business development in five divisions of activities based on itsown technologies. Since 2001, the DDS Development Division is organized within NOF's family ofcomplementary business units, offering innovation to pharmaceutical and biomedical products. In
April 2023, the DDS Development Division was renamed the Life Science Division and will continue tocontribute to the pharmaceutical and medical fields. NOF supplies high-purity phospholipids, PEG
diacylglycerols and proprietary ionizable lipids as materials for LNP. For additional information, visit
www.nof.co.jp/english/business/life and dds-drug.com or follow us on LinkedIn.
About Phosphorex
Phosphorex is a leading provider of drug delivery technologies and solutions. By harnessing thepotential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions
and enabling technologies to optimize a drug’s release rate, targeting ability, bioavailability, anddeliverability, with the goal of achieving desired therapeutic effects while reducing adverse clinicaloutcomes. Phosphorex supports pharmaceutical and biotech companies through all phases of theirdevelopment, from proof of concept to clinical studies. Phosphorex’s mission is to help our partners
solve complex problems and develop successful drugs to help patients. Additional information about
Phosphorex is available at www.phosphorex.com or follow us on LinkedIn.
About Ampersand Capital Partners
Founded in 1988, Ampersand Capital Partners is a middle market private equity firm with $3 billionof assets under management dedicated to growth-oriented investments in the healthcare sector.
With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend ofprivate equity and operating experience to build value and drive long-term performance alongside its
portfolio company management teams. Ampersand has helped build numerous market-leading
companies across each of the firm’s core healthcare sectors. For additional information, visit
www.ampersandcapital.com or follow us on LinkedIn.
[Contact]
NOF CORPORATIONLife Science Division
Tel: +91-3-5424-6771 E-Mail: ddsinfo@nof.co.jp
https://www.nof.co.jp/english/business/life
https://dds-drug.com/